BRAF and neoplasm: Thus, it would be interesting to know at least the mutational status of BRAF according to primary tumor location in the surgical samples of the patients enrolled in the clinical trials included in the present meta-analysis in order to interpret the results on the different outcome reached in RCC and LCC.